---
title: "ASCLETIS-B granted a total of 650,000 stock options"
description: "According to the announcement from ASCLETIS-B, the company granted stock options to 10 participants (grantees) on September 30, 2025, under the stock option plan adopted by the company on February 3, "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259561720.md"
published_at: "2025-09-30T14:09:03.000Z"
---

# ASCLETIS-B granted a total of 650,000 stock options

> According to the announcement from ASCLETIS-B, the company granted stock options to 10 participants (grantees) on September 30, 2025, under the stock option plan adopted by the company on February 3, 2025 (2025 Stock Option Plan), to subscribe for a total of 650,000 shares of the company's common stock with a par value of USD 0.0001 per share

According to the announcement from Ascletis Pharma-B (01672), the company granted stock options to 10 participants (grantees) under the stock option plan adopted on February 3, 2025, to subscribe for a total of 650,000 shares of the company's common stock with a par value of USD 0.0001 per share on September 30, 2025

### Related Stocks

- [01672.HK - ASCLETIS-B](https://longbridge.com/en/quote/01672.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| GIC Private Limited 以每股 12.18 港元的价格，投资了歌礼制药-B，共计 64,128,000 股 | 新加坡政府投资公司（GIC Private Limited）通过以每股 12.18 港元的价格购买 64,128,000 股，获得了歌礼制药的股份，总金额约为 7.8108 亿港元（1 亿美金）。此次投资使 GIC 在该公司中持有 6.42 | [Link](https://longbridge.com/en/news/275105288.md) |
| 歌礼制药通过私人股份配售筹集了 8.44 亿港元 | 歌礼制药公司成功通过私募发行 69,256,000 股新股，筹集了 844 百万港元，每股价格为 12.18 港元。这些股份向至少六家机构投资者提供，并根据美国证券法的 S 条款和 144A 规则在美国以外进行配售，未在美国进行任何公开发行 | [Link](https://longbridge.com/en/news/275434090.md) |
| GIC 向歌礼制药（1672.HK）投资 1 亿美元：锚定中国核心创新药资产的长期资本 | GIC 通过以每股平均 12.18 港元的价格收购 64,128,000 股，向 Ascletis Pharma（1672.HK）投资了约 1 亿美元。这项投资标志着 GIC 进入 Ascletis Pharma 的股东基础，突显出对中国创 | [Link](https://longbridge.com/en/news/275106794.md) |
| 歌礼制药通过配售股份筹集 8.35 亿港元，以资助肥胖药物的试验 | 歌礼制药计划通过以每股 12.18 港元的价格配售 69,256,000 股新股，筹集约 8.35 亿港元，约占其现有股本的 6.98%。这些资金将主要用于支持其肥胖药物 ASC30 的全球第三阶段临床试验，其余部分用于营运资金。此次配售需 | [Link](https://longbridge.com/en/news/274573426.md) |
| 歌礼制药宣布进行新股的私人配售 | 歌礼制药公司宣布在一般授权下进行新股的私募发行。这些股份将仅向符合条件的机构投资者提供，符合美国证券法第 144A 条款的注册要求豁免，并根据 S 条款在美国以外出售。美国不计划进行公开发行 | [Link](https://longbridge.com/en/news/274571020.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
